This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Barlass U, Dutta R, Cheema H, George J, Sareen A, Dixit A, et al. Morphine worsens the severity and prevents pancreatic regeneration in mouse models of acute pancreatitis. Gut 2018, 67: 600–602.
Bang S, Yoo J, Gong X, Liu D, Han Q, Luo X, et al. Differential inhibition of Nav1.7 and neuropathic pain by hybridoma-produced and recombinant monoclonal antibodies that target Nav1.7: Differential activities of Nav1.7-targeting monoclonal antibodies. Neurosci Bull 2018, 34: 22–41.
Minett MS, Nassar MA, Clark AK, Passmore G, Dickenson AH, Wang F, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun 2012, 3: 791.
Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444: 894–898.
Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 2007, 71: 311–319.
Emery EC, Luiz AP, Wood JN. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets 2016, 20: 975–983.
Minett MS, Pereira V, Sikandar S, Matsuyama A, Lolignier S, Kanellopoulos AH, et al. Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7. Nat Commun 2015, 6: 8967.
Talley EM, Solorzano G, Lei Q, Kim D, Bayliss DA. CNS distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci 2001, 21: 7491–7505.
Turner PJ, Buckler KJ. Oxygen and mitochondrial inhibitors modulate both monomeric and heteromeric TASK-1 and TASK-3 channels in mouse carotid body type-1 cells. J Physiol 2013, 591: 5977–5998.
Rusznak Z, Pocsai K, Kovacs I, Por A, Pal B, Biro T, et al. Differential distribution of TASK-1, TASK-2 and TASK-3 immunoreactivities in the rat and human cerebellum. Cell Mol Life Sci 2004, 61: 1532–1542.
Gnatenco C, Han J, Snyder AK, Kim D. Functional expression of TREK-2 K+ channel in cultured rat brain astrocytes. Brain Res 2002, 931: 56–67.
Bayliss DA, Barrett PQ. Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends Pharmacol Sci 2008, 29: 566–575.
Ge F, Mu P, Guo R, Cai L, Liu Z, Dong Y, et al. Chronic sleep fragmentation enhances habenula cholinergic neural activity. Mol Psychiatry 2019. doi: https://doi.org/10.1038/s41380-019-0419-z.
Yao C, Li Y, Shu S, Yao S, Lynch C, Bayliss DA, et al. TASK channels contribute to neuroprotective action of inhalational anesthetics. Sci Rep 2017, 7: 44203.
Gotter AL, Santarelli VP, Doran SM, Tannenbaum PL, Kraus RL, Rosahl TW, et al. TASK-3 as a potential antidepressant target. Brain Res 2011, 1416: 69–79.
Morenilla-Palao C, Luis E, Fernandez-Pena C, Quintero E, Weaver JL, Bayliss DA, et al. Ion channel profile of TRPM8 cold receptors reveals a role of TASK-3 potassium channels in thermosensation. Cell Rep 2014, 8: 1571–1582.
Cotten JF. TASK-1 (KCNK3) and TASK-3 (KCNK9) tandem pore potassium channel antagonists stimulate breathing in isoflurane-anesthetized rats. Anesth Analg 2013, 116: 810–816.
Wright PD, Veale EL, McCoull D, Tickle DC, Large JM, Ococks E, et al. Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3. Biochem Biophys Res Commun 2017, 493: 444–450.
Garcia G, Noriega-Navarro R, Martinez-Rojas VA, Gutierrez-Lara EJ, Oviedo N, Murbartian J. Spinal TASK-1 and TASK-3 modulate inflammatory and neuropathic pain. Eur J Pharmacol 2019, 862: 172631.
Liao P, Qiu Y, Mo Y, Fu J, Song Z, Huang L, et al. Selective activation of TWIK-related acid-sensitive K+ 3 subunit-containing channels is analgesic in rodent models. Sci Transl Med 2019, 11. pii: eaaw8434.
The authors’ research is supported by the National Key R&D Program of China (2019YFC1709101), The Project First-Class Disciplines Development of Chengdu University of TCM (CZYHW1901), São Paulo Research Foundation (FAPESP 2018/07366-4), the National Natural Science Foundation of China (81904312 and 81774437), and the Sichuan Science and Technology Program, China (2019YFH0108, 2018HH0123, and 2018SZ0257).
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Ren, WJ., Ulrich, H., Semyanov, A. et al. TASK-3: New Target for Pain-Relief. Neurosci. Bull. 36, 951–954 (2020). https://doi.org/10.1007/s12264-020-00516-4